Colorectal Cancer (CRC) is one of the most common cancers with a high rate of morbidity and mortality
worldwide. It has been demonstrated that epigenetic alterations which may cause changes in the expression of
microRNA, DNA methylation and histone acetylation that results in inheritable modifications in gene expression
in colorectal epithelial cells, plays a crucial role in the development of CRC. Recently, targeting epigenetic modification
has emerged as a potentially important treatment approach in CRC. The US Food and Drug Association
has approved the use of some epigenetic drugs that may be able to inhibit or reverse these alterations and also
enhance sensitivity to chemotherapeutic agents and radiotherapy in CRC. In this review we have summarized the
recent pre-clinical and clinical trial studies investigating the therapeutic value of using epigenetic drugs as novel
therapeutic approach in CRC treatment.
Keywords: Epigenetic, colorectal cancer, drug, DNA methylation, microRNA, histone acetylation, chemotherapeutic agents.
Rights & PermissionsPrintExport